|drug3328||Symptoms questionnare Wiki||0.71|
|drug1422||Group Social ABCs Wiki||0.71|
|D001321||Autistic Disorder NIH||0.24|
|D000067877||Autism Spectrum Disorder NIH||0.21|
|D045169||Severe Acute Respiratory Syndrome NIH||0.03|
There are 2 clinical trials
The 2019-20 coronavirus disease, caused by COVID-19, is an ongoing pandemic. The measures in which public health officials quarantine confirmed and isolate symptomatic cases in order to reduce the spread COVID-19 is the common practice used in most countries. However, a significant question remains in regards to the asymptomatically infected individuals, which may propagate the virus and impede infection control. The other question to consider is whether these asymptomatic carriers develop an immune response or continue viral shedding. The purpose of the current study is the evaluate the immune response, i.e developing anti-SARS-CoV-2 antibodies in the asymptomatic cases, in a household study design. We plan to evaluate over 1000 patients with positive COVID-19 results and their households.
Description: The percentage of symptomatic patients who developed either IgM/IgG/IgA response within 100 days from COVID-19 InfectionMeasure: Proportion of symptomatic patients with immune response (IgM/IgG/IgA) Time: 100 days
Description: The percentage of Asymptomatic patients who developed either IgM/IgG/IgA response within 100 days from COVID-19 InfectionMeasure: Proportion of Asymptomatic patients with immune response (IgM/IgG/IgA) Time: 100 days
Description: the mean time patients devleoped IgMMeasure: Time to IgM Time: Evaluated within a 100 days followup
Description: the mean time patients devleoped IgGMeasure: Time to IgG Time: Evaluated within a 100 days followup
Description: the mean time patients devleoped IgGMeasure: Time to IgA Time: Evaluated within a 100 days followup
Description: Cohen's kappa coefficient calculated between the different serology kits used for evaluationMeasure: Serology kits inter-observer agreement Time: Evaluated within a 100 days followup
The novel coronavirus (SARS-CoV-2) has spread all around the world and testing has posed a challenge globally. Health care providers are highly exposed and are an important group to test. On top of these concerns, health care workers are also stressed by the needs on responders in the COVID-19 crisis. The investigators will look at different ways to measure how common COVID-19 is among health care workers, how common is the presence of antibodies by serological tests (also known as serostatus). The investigators will describe health worker mental and emotional well-being and their coping strategies in their institutional settings. Lastly, the investigators will describe how knowing serostatus can affect individuals' mental and emotional well-being and how to cope in the midst of the COVID-19 response. This will help to how to better test and help healthcare workers in the COVID-19 pandemic and prepare for possible future outbreaks.
Description: Percentage of health care workers with positive serological markers to describe patterns in exposure, re-infection, clinical symptom, serological responses among health care workers based on their baseline serological status over a one year period.Measure: Proportion seropositive Time: Up to 12 months after collection visit
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports